A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease.

Dement Geriatr Cogn Dis Extra · 2011 · PMC3199883 · PMID 22163242

Europe PMC DOI

hedged sentences

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

borderline significancep = 0.049actually significant

While this was not statistically significant for either patch size versus placebo (41/267 of participants; 15.4%) in the ITT-LOCF population, the 10-cm 2 rivastigmine patch did reach statistical significance versus placebo in the ITT-OC population (p = 0.034) and borderline significance in the MITT population (p = 0.049).

also in 7,017 other papers

did not reach statistical significanceno p-value reported

Participants receiving the rivastigmine patch showed numerically less decline versus placebo at week 24 on the CIBIC plus-J, although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.